If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-16. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
| Property | Value | Notes |
|---|---|---|
| Water content | Low in freshly lyophilised material | Rises after repeated opening of the same vial |
| Solution stability | Lower than powder stability | Frozen aliquots are preferred over repeated thawing |
| Purity assessment | Reversed-phase HPLC with UV detection | Peak-area percentage excludes salts and water |
| Salt form | Often the trifluoroacetate salt | Retained from acidic purification gradients |
| Light sensitivity | Not strongly photoreactive | Dark storage still advised for long-term keeping |
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
=== Oxidative addition === Oxidative addition to the 14-electron Pd(0) complex is proposed. This process gives a 16-electron Pd(II) species. It has been suggested that anionic ligands, such as OAc, accelerate this step by the formation of [Pd(OAc)(PR3)n]−, making the palladium species more nucleophillic. In some cases, especially when an sp3-hybridized organohalide is used, an SN2 type mechanism tends to prevail, yet this is not as commonly seen in the literature. However, despite normally forming a cis-intermediate after a concerted oxidative addition, this product is in rapid equilibrium with its trans-isomer.
In Portal, the player controls the protagonist, Chell, from a first-person perspective as she navigates a series of test chambers using the Aperture Science Handheld Portal Device, commonly known as the portal gun, under the supervision of the artificial intelligence GLaDOS. The portal gun can create two distinct portal ends, blue and orange, which connect different locations within the test chambers. The portals form a connection between two points in three-dimensional space, allowing Chell and objects to pass between them. Neither portal functions exclusively as an entrance or exit, as objects entering one emerge from the other. The game's physics preserve an object's momentum as it passes through a portal, while its trajectory is determined by the orientation of the exit portal. A common maneuver involves placing one portal below the player, falling through it to gain speed, and emerging from another portal positioned on a wall or other surface. This technique allows the player to redirect momentum and launch Chell or objects across gaps and other obstacles. The technique is commonly referred to as "flinging". When portal surfaces are positioned at different orientations, the player's orientation changes when passing through them so that the character remains aligned with the game's gravitational direction. Chell and objects that fit through the portal openings can pass between them, while portals cannot be fired through an existing open portal. Portals cannot be placed on moving objects, glass, certain surfaces, liquids, or areas that are too small to accommodate them.
== Accidents == Ethylene oxide is extremely flammable, and its mixtures with air are explosive. When heated it may rapidly expand, causing fire and explosion. Several industrial accidents have been attributed to ethylene oxide explosion. The autoignition temperature is 429 °C (804 °F), decomposition temperature of 571 °C (1,060 °F) at 101.3 kPa (14.69 psi), minimum inflammable content in the air is 2.7%, and maximum limit is 100%. The NFPA 704 rating is Health, 3; Flammability, 4; Instability 2. Ethylene oxide in presence of water can hydrolyze to ethylene glycol and form polyethylene oxide, which then eventually is oxidized by air and leads to hotspots that can trigger explosive decomposition. Fires caused by ethylene oxide are extinguished with conventional media including foam, carbon dioxide, or water. Suppression of this activity can be done by blanketing with an inert gas until total pressure reaches the nonexplosive range. Extinguishing of burning ethylene oxide is complicated by its ability to continue burning in an inert atmosphere and in water solutions. Fire suppression is reached only upon dilution with water above 22:1.
Naftali Loewenthal, member of the Chabad Hasidic community; main area of study is Hasidism and Jewish Mysticism; professor in the Department of Hebrew and Jewish Studies at University College London; director of the Chabad Research Unit, a division of the Chabad-Lubavitch movement in United Kingdom; author of Communicating the Infinite: The Emergence of the Habad School (1990); also authored Hasidism Beyond Modernity: Essays in Habad Thought and History (2019) as well as many scholarly articles and publications on the Chabad mysticism; also extensively written on history of Chabad Hasidic women. Nick Lowles, founder of Hope Not Hate and former editor of the anti-fascist Searchlight (magazine), backed by various politicians and celebrities several trade unions. Knowles is the author of a number of books on football violence, right wing groups and antisemitism in Britain. He was a freelance investigative journalist, working in television, including on BBC Panorama, World in Action, Channel Four Dispatches and MacIntyre Undercover. Moshé Machover (Hebrew: משה מחובר; born 1936) is a mathematician, philosopher, pro Palestinian socialist anti-Zionist activist and author, noted for his writings critical of Israel and Zionism. David Magarshack (23 December 1899 – 26 October 1977); author, translator and biographer of Russian authors, best remembered for his translations of Dostoevsky, Chekhov and Nikolai Gogol; of Russian Jewish ancestry. Miriam Margolyes (born 18 May 1941) is a British and Australian actress.
Sources: en.wikipedia.org
== Pathology == Haptotaxis plays a role in several kinds of diseases where the movement or aggregation of cells causes the symptoms. As mentioned before, cancers that are metastatic have the ability to perform haptotaxis in order to spread throughout the body. This ability is not limited to tumor cells. Idiopathic pulmonary fibrosis (IPF) is a disease marked by fibrosis in lung mesothelial cells. TGF-β1 is a cytokine found in higher concentrations of lungs from patients who have IPF, and induces haptotaxis of pleural mesothelial cells. At the same time, TGF-β1 causes the mesothelial cells to develop into myofibroblasts, which contribute to the symptoms in IPF. The result is that there becomes an aggregation of myofibroblasts in the lungs, which leads to fibrosis of the mesothelial cells. During nephritis, VCAM-1 is expressed in higher levels on the tubules of nephrons, which leads to increased leukocyte migration via the gradient established by VCAM-1. This increased expression was not found on the capillary endothelial cells. This migration of leukocytes leads to inflammation and tissue destruction characteristic of an inflammatory response.
Prime Minister Rishi Sunak meets with US president Joe Biden at the Grand Central Hotel in Belfast. Biden makes a keynote speech at the Ulster University during which he urges Northern Ireland's politicians to restore the power-sharing government. A 74-year-old man is extradited from Pakistan and charged with murdering police officer Sharon Beshenivsky in November 2005. Tesco reduces the price of a four pint bottle of milk from £1.65 to £1.55 following a cut in wholesale prices. Coronation of Charles III and Camilla: Buckingham Palace confirms that the Duke of Sussex will attend the coronation, but that the Duchess will remain in the United States with their children. 13 April Data published by the Office for National Statistics shows a 0% growth in the UK economy during February as growth in the construction industry was offset by industrial action. Publication of the Deciphering Developmental Disorders study, a study involving children with development disorders, which has identified 60 new health conditions. Sainsbury's follows Tesco in cutting the price of milk. A report published by Diabetes UK indicates the UK is heading for what the charity describes as a "rapidly escalating diabetes crisis", with 4.3 million people experiencing a form of diabetes, a further 850,000 estimated to be living with the disease but unaware of it, and another 2.4 million people at risk of developing the condition. Cases of diabetes are more prevalent in less affluent areas of the country. 14 April Ford receives government approval for its "BlueCruise" Level 2 autonomous driving technology.
== Predicting from DNA/RNA sequences == In biology, proteins are produced by translation of messenger RNA (mRNA) with the protein sequence deriving from the sequence of codons in the mRNA. The mRNA is itself formed by the transcription of genes and may be further modified. These processes are sufficiently understood to use computer algorithms to automate predictions of protein sequences from DNA sequences, such as from whole-genome DNA-sequencing projects, and have led to the generation of large databases of protein sequences such as UniProt. Predicted protein sequences are an important resource for protein identification by mass spectrometry. Historically, short protein sequences (10 to 15 residues) determined by Edman degradation were back-translated into DNA sequences that could be used as probes or primers to isolate molecular clones of the corresponding gene or complementary DNA. The sequence of the cloned DNA was then determined and used to deduce the full amino-acid sequence of the protein.
Richard Küch (1860-1915) was able to melt quartz glass - the basis for UV radiation sources - for the first time in 1890 and founded the Heraeus Quarzschmelze. He developed the first quartz lamp (sun lamp) for generating UV radiation in 1904, thus laying the foundation for this form of light therapy. Despite the dosage problems, doctors increasingly used quartz lamps in the early 20th century. Internal medicine specialists and dermatologists were among the most eager testers. After successful treatment of skin tuberculosis, internal medicine began to treat tuberculous pleurisy, glandular tuberculosis and intestinal tuberculosis. In addition, doctors tested the effect of quartz lamps on other infectious diseases such as syphilis, metabolic diseases, cardiovascular diseases, nerve pain such as sciatica, or nervous diseases such as neurasthenia and hysteria. In dermatology, fungal diseases, ulcers and wounds, psoriasis, acne, freckles and hair loss were also treated with quartz lamps, while in gynecology, abdominal diseases were treated with quartz lamps. Rejuvenation specialists used artificial high-altitude sunlight to stimulate gonadal activity and treated infertility, impotentia generandi (inability to conceive), and lack of sexual desire by irradiating the genitals. For this purpose, Philipp Keller (1891-1973) developed an erythema dosimeter with which he measured the amount of radiation not in Finsen units (UV radiation with a wavelength λ of 296.7 nm and an irradiance E of 10−5 W/m2), but in height solar units (HSE).
=== Diversification and decline === The ensuing financial crisis prompted a major strategic transition. In 1970, HVEC's losses represented 31 percent of total stockholder investment. The company laid off 100 employees and suspended many research programs, citing insufficient federal funding for basic physics research. That year also marked a leadership transition: Pascal Levesque, head of the profitable HVEC subsidiary Electronized Chemicals Corporation, became president and chief executive, while departing president Denis Robinson assumed the chairmanship held by Trump. Under new management, HVEC diversified into industrial applications of its accelerator technologies. By 1972, the company had reorganized as a miniconglomerate with more than ten subsidiaries manufacturing plastics, power equipment, and radiation processing systems—products enabled by particle accelerators rather than particle accelerators themselves. The diversification strategy yielded several commercially successful products. Electronized Chemicals Corporation's heat-shrink tubing, made by electron-beam crosslinking of polyethylene, became ubiquitous in electrical wiring. The technology enabled modern wire harnesses in automobiles and aircraft, where compact, reliable insulation was essential. Ion Physics Corporation introduced radiation-based ion implantation, enabling precise control of transistor characteristics in integrated circuits. HVEC closed Ion Physics in 1971, but became standard practice throughout the global semiconductor industry by the late 1970s.
Sources: en.wikipedia.org
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.
Mass spectrometry confirms identity, because the measured mass is compared with the value expected from the sequence. Chromatography mainly reports how much of the material elutes as the target peak.
It usually describes the share of the chromatographic peak area recorded at a set wavelength. Salts, residual water, and solvent are excluded from that number, so it is not the same as mass fraction.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.